RE:RE:RE:CAR-T updateNovember 21, 2024 - Novartis is betting on direct cellular engineering through a collaboration with [oncolytic virus company] Vyriad, the companies announced Wednesday. “As an industry pioneer in the field, we are committed to addressing unmet medical needs and making the transformative potential of CAR-T cell therapies available to more patients,” stated Jennifer Brogdon, who leads Novartis Biomedical Research’s Cell & Gene Therapies division, in the announcement of the deal. “We are excited to collaborate with Vyriad and combine their technology platform with Novartis expertise and capabilities to innovate and advance next-generation CAR-T cell therapies.” CAR-T therapies have become a more common method as a way to treat cancer in recent years. However, it is expensive and time consuming as the current approach is to remove cells from a patient, ship them to a lab to be genetically altered and then sent back to be infused back into the patient.
The new collaboration between Vyriad and Novartis is based around Vyriad’s targeted lentiviral vector platform, which can genetically modify a patient’s T cells directly within their body. That eliminates the steps, cost and time in the process.
Vyriad does not have any clinical trials running in CAR-T therapy.
[ As previously reported MAYO's Dr. Richard Vile has demonstrated that ONCY's pelareorep is putatively capable of modifying a patient's T cells directly within their body to potentially affect a "cure" through the administration of a CAR-T therapy + pelareorep followed by a single IV delivered pelareorep 'boost' ]
https://www.postbulletin.com/business/vyriad-signs-huge-deal-with-novartis-to-develop-new-cancer-treatments Vyriad is an oncolytic virus (OV) company that is developing an intravenous VSV - OV therapy for the treatment of multiple cancers. https://vyriad.com/clinical-programs/
https://vyriad.com/science/oncolytic-virus-platforms/vsv-platform/ November 01, 2024 - The FDA is reconsidering serious safety warnings on CAR-T therapies with plans to change them potentially, Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research (CBER), said in an interview with Fierce Pharma.